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Essentials
• Microbe-dependent production of trimethylamine N-oxide (TMAO) contributes to thrombosis risk.
• The impact of host flavin monooxygenase 3 (FMO3) modulation on platelet function is unknown.
• Genetic manipulation of FMO3 in mice alters systemic TMAO levels and thrombosis potential.
• Genetic manipulation of FMO3 is associated with alteration of gut microbial community structure.
Summary. Background: Gut microbes play a critical role in the production of trimethylamine N-oxide (TMAO), an atherogenic metabolite that impacts platelet responsiveness and thrombosis potential. Involving both microbe and host enzymatic machinery, TMAO generation utilizes a metaorganismal pathway, beginning with ingestion of trimethylamine (TMA)-containing dietary nutrients such as choline, phosphatidylcholine and carnitine, which are abundant in a Western diet. Gut microbial TMA lyases use these nutrients as substrates to produce TMA, which upon delivery to the liver via the portal circulation, is converted into TMAO by host hepatic flavin monooxygenases (FMOs). Gut microbial production of TMA is rate limiting in the metaorganismal TMAO pathway because hepatic FMO activity is typically in excess.
Objectives: FMO3 is the major FMO responsible for host generation of TMAO; however, a role for FMO3 in altering platelet responsiveness and thrombosis potential in vivo has not yet been explored. Methods: The impact of FMO3 suppression (antisense oligonucleotide-targeting) and overexpression (as transgene) on plasma TMAO levels, platelet responsiveness and thrombosis potential was examined using a murine FeCl 3 -induced carotid artery injury model. Cecal microbial composition was examined using 16S analyses. Results: Modulation of FMO3 directly impacts systemic TMAO levels, platelet responsiveness and rate of thrombus formation in vivo.
Microbial composition analyses reveal taxa whose proportions are associated with both plasma TMAO levels and in vivo thrombosis potential. Conclusions: The pre
Introduction
Acute thrombotic events represent a leading cause of death and disability in aging populations worldwide [1] . A critical element of thrombosis development is the ability of platelets to become activated, undergo degranulation and clot formation, and promote hemostasis [2] . Importantly, the presence of cardiovascular disease (CVD) and many CVD risk factors are associated with both heightened platelet reactivity and thrombosis risk [3] [4] [5] [6] [7] . Despite the contribution of platelet responsiveness to thrombotic event risk [8, 9] , a clear understanding of the mechanisms that modulate platelet responsiveness and thrombosis susceptibility are not fully defined. Moreover, although antiplatelet agents are a major tool in the current therapeutic arsenal for CVD, their more widespread use is limited by adverse bleeding complications [10, 11] . Recent studies show both clinical and mechanistic links between gut microbiota and CVD-related phenotypes, including atherosclerosis [12] [13] [14] [15] , adverse ventricular remodeling and heart failure [16] [17] [18] , and platelet responsiveness and thrombosis potential [19] . Specifically, the gut microbiota-derived metabolite trimethylamine-Noxide was shown to contribute to CVD pathogenesis in clinical and basic studies spanning metabolomics, largescale clinical investigations, microbial transplantation studies and animal models of CVD [12] [13] [14] [15] [16] [17] [18] [19] [20] . In studies involving over 4000 subjects, plasma levels of trimethylamine-N-oxide (TMAO) independently predicted incident thrombotic event risk (heart attack and stroke) [19] . Moreover, exposure of human platelets to physiological levels of TMAO altered intracellular calcium signaling, increasing platelet responsiveness to multiple agonists. Dietary choline supplementation was shown to increase plasma TMAO levels, platelet responsiveness and thrombosis potential in multiple animal models [19] . Importantly, distinct microbial transplantation studies demonstrate trimethylamine (TMA)/TMAO production capacity with corresponding atherosclerosis and thrombosis potential are all transmissible phenotypes [19, 21] . Finally, recent clinical studies show subjects taking choline supplements have increased plasma TMAO and heightened platelet responsiveness studies [22] .
Production of TMAO occurs via a metaorganismal pathway, relying on the sequential action of both microbial and host enzyme activities. Choline, phosphatidylcholine (lecithin) and carnitine, TMA-containing nutrients abundant in a Western diet, serve as the major dietary precursors for TMAO. When TMA-containing nutrients reach the colon, they also serve as nutrients for some microbes, resulting in generation of TMA [12] . TMA produced is transported via the portal circulation to the liver, where flavin monooxygenases (FMOs) can catalyze the conversion of TMA into TMAO [23, 24] . Of the FMOs, FMO3 serves as the major source of TMA [23] and is the target in the rare genetic disorder trimethylaminuria, also known as 'fish odor syndrome' [25, 26] . Of note, no CVD or thrombosis-related phenotypes are reported with trimethylaminuria. However, FMO3 deficiency leads to low TMAO levels, which is predicted to be associated with reduced risk of thrombosis or atherosclerosis, and thus might be difficult to detect in clinical populations. Antisense oligonucleotide (ASO)-induced FMO3 suppression in mice is reported to reduce TMAO levels and inhibit both atherosclerosis and tissue sterol metabolism [27] [28] [29] . The impact of FMO3 activity on platelet function is unknown. Herein we performed genetic manipulation of host FMO3 to determine the impact on TMAO levels, platelet responsiveness and thrombosis potential in vivo.
Materials and methods

General procedures and reagents
Reagents were purchased from Sigma unless otherwise stated. Hepatic FMO activity was quantified using liver homogenate and d9-TMA substrate, monitoring NADPH-dependent production of d9-TMAO [19] .
Ethical considerations
All animal model studies were approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic.
Mouse ex vivo platelet aggregometry studies
Platelet-rich plasma (PRP) was generated as described [5] . Diluted platelet-poor plasma was prepared by further centrifugation at 800 9g for 2 min. Platelets were counted using a hemocytometer and concentrations adjusted to 2 9 10 8 mL À1 with platelet-poor plasma. CaCl 2 and MgCl 2 (both 1 mM final) were added immediately before platelet aggregation studies, which were assessed at 37°C using a dual channel Type 500 VS aggregometer (Chrono-log, Havertown, PA, USA) with stirring at 1200 rpm.
Flow cytometry
To prepare isolated platelets, 100 nM prostaglandin E1 was added to PRP and then centrifuged at 100 9g (5 min, 22°C). The platelet pellet was gently washed with a modified phosphate buffer saline (12 mM Na [PO 4 ], pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 and 5.5 mM glucose) with 100 nM prostaglandin E1, centrifuged again (500 9g, 5 min), and then resuspended in modified Tyrode's buffer (12 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 5 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 5.6 mM glucose, 0.35 gm% bovine serum albumin, pH 7.4). P-selectin cell-surface expression was quantified by flow cytometry using FITC-conjugated CD62p antibody (BD Biosciences, Billerica, MA, USA; Cat# 553744; 1/ 100 dilution, 10 min incubation, 22°C). Isotype control antibody (BD Biosciences; Cat# 553995) was used in parallel to assess non-specific binding. Data are presented as median fluorescence intensity (mean AE standard deviation [SD] ). Samples were analyzed on an LSRII flow cytometer (BD Biosciences) and data analyzed using FlowJo V10 software (Tree Star, Ashland, OR, USA).
Antisense oligonucleotide-mediated knock-down of murine FMO3
Antisense oligonucleotide-mediated knock-down was accomplished using 20-mer phosphorothioate ASOs containing 2 0 -0-methoxyethyl groups at positions 1-5 and 15-20. Targeted suppression of FMO3 was confirmed by western analyses of liver homogenates, suppression of liver homogenate FMO activity and plasma TMAO levels. ASOs used in this work were prepared as previously described [30] by IONIS Pharmaceuticals, Inc. (Carlsbad, CA, USA). For initial studies, C57BL/6J mice were injected intraperitoneally twice weekly with 25 mg kg À1 of either non-targeting control ASO (5 0 -TCCCATTTCAGGAGACCTGG-3 0 ) or ASO directed against murine FMO3 (5 0 -TGGAAGCATTTGCCTT-TAAA-3 0 ) [29] . For the FMO3 ASO studies in Fig. 4 , C57BL/6N mice were injected (12.5 mg kg
À1
) intraperitoneally twice a week for 6 weeks using either a new nontargeting cET (constrained ethyl chemistry) control ASO (GGCCAATACGCCGTCA) or cET FMO3 ASO (TTTTTTACCGTGCTTT). Unless otherwise indicated, mice were maintained on chemically defined diets supplemented in choline (1.0%). All ASO-targeted loss-of-function experiments were performed in female mice because of the marked suppression of fmo3 in post-pubertal male mice [23] .
Immunoblotting assay
Total protein was quantified using the bicinchoninic acid assay (Bio-Rad, Hercules, CA, USA) [31] . Proteins (50 lg) were separated by 4-12% SDS-PAGE, transferred to polyvinylidene difluoride membranes, and detected after incubation with specific antibodies: anti-FMO3 rabbit polyclonal (ABCAM #Ab126790, Cambridge, MA, USA), anti-glyceraldehyde-3-phosphate dehydrogenase [GAPDH] rabbit monoclonal (Cell Signaling Technologies #5174, Danvers, MA, USA) and b-actin (Cell Signaling Technologies #3700). ImageJ was used for densitometric analysis.
Liver FMO activity assay, choline TMA lyase activity assay and mass spectrometry Total FMO activity in liver homogenate quantified flavindependent d9-TMAO production from d9-TMA using liquid chromatography/tandem-mass spectrometry (LC/ MS/MS) analyses with d4-choline as internal standard, as previously described [12] . Stable isotope dilution LC/MS/ MS was used to quantify TMA, TMAO and choline in plasma and animal diets, as previously described [12, 32] . Microbial choline TMA lyase activity was quantified by monitoring d9-TMA production from d9-choline substrate using LC/MS/MS analyses [15] . Reactions were stopped by addition of methanolic acidified d4-choline and 13 C 3 , 15 N 1 -TMA internal standard mix, and deproteinated reaction mixtures analyzed on a Shimadzu (Columbia, MD, USA) 8050 triple quadrupole mass spectrometer with UHPLC interface.
Carotid artery thrombosis model
Mice were subjected to common carotid artery FeCl 3 -induced injury, and thrombus formation monitored in real time using intravital fluorescence microscopy and continuous video image capture [19] . Time to cessation of blood flow was determined through inspection of computer images as previously described [19] by two data analysts blinded to animal group assignments.
Real-time PCR analysis
Expression levels of mRNA were calculated based on the ΔΔÀCT method. qPCR was conducted using the Applied Biosystems (Beverly, MA, USA) 7500 Real-Time PCR System. Hepatic fmo3 gene expression, normalized to Cyclophilin A expression, was quantified using the following primers: FMO3 (Fwd: CCCACATGCTTTGAGAG GAG; Rev: GGAAGAGTTGGTGAAGACCG); Cyclophilin A (Fwd: GCGGCAGGTCCATCTACG; Cyclophilin A Rev: GCCATCCAGCCATTCAGTC).
Whole blood in vitro thrombosis assay
Microfluidics experiments were performed using the Cellix Microfluidics System (Cellix Ltd, Dublin, Ireland) as previously described [19] . Where indicated, channels of a Vena8 Fluoro+ biochip were coated with type 1 collagen (150 lg mL
À1
). Images of the biochip were collected using an HC Plan Apo 20X/0.7NA lens on a Leica DMI6000 (W.Nuhsbaum Inc, McHenry, IL, USA) inverted microscope equipped with cooled CCD camera. Whole blood from consenting healthy volunteers was fluorescently tagged with Calcein AM and pretreated with TMAO (100 lM, pH 7.4) or normal saline (30 min, 22°C) as indicated. Blood was perfused over chips at physiological shear rate (67.5 dynes cm À2 ) for 3 min and fluorescent platelets adhering to the collagen coating were captured every 2 s. At the end of the experiment, PBS was drawn through the biochip channels at 2.5 dynes, and 10 images were also captured along the length of the channel. Platelet adherence to the chip surface was quantified with computer-assisted tomographic analyses [19] .
Bleeding time determination
Bleeding time was examined using a tail tip amputation model [33] . Briefly, mice were anesthetized and maintained on a warming pad, and a consistent injury was made 3 mm from the tip of the tail. The tail was immersed in normal saline maintained at 37°C and the cumulative bleeding time was recorded.
Human liver-specific FMO3 transgenic mice Two different liver-specific human FMO3 transgenic (FMO3-transgenic) mouse lines were used. Both demonstrated comparable liver FMO3 expression and plasma TMAO levels and showed comparable phenotypes. For most experiments, the human FMO3-TG mice used were the same as recently described [23] . Briefly, C57BL/6J mice were engineered to contain a liver-specific human FMO3 transgene DNA construct containing 2.2 kb of mouse albumin enhancer/promoter region, the human FMO3 full-length cDNA (1.6 kb) and SV40 intron/polyA sequence (0.9 kb). The transgene DNA construct was microinjected into fertilized eggs of C57BL/6J mice, and the highest FMO3 expressing line was maintained through heterozygous breeding to wild-type (WT) C57BL/6J mice [23] . This original human FMO3-TG mouse line unfortunately was lost. Consequently, a second hepatocyte-specific human FMO3-TG line was generated using full-length human FMO3 cDNA (NM_006894) PCR cloned into the hepatocyte-specific transgenic vector pLiv11 (PMID:19965599) (used only for Fig. 6C ). Briefly, ClaI sites were added to 5 0 and 3 0 ends, respectively, of human FMO3 cDNA. This cDNA was then cloned into the ClaI restriction site of the pLiv-11 construct. The transgene cassette including human apoE promoter, human FMO3 cDNA and human apoE hepatic control region was released from the construct by NotI/SpeI digestion. After purification, the transgene was introduced via pro-nuclear microinjection into C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA). Transgenic founder lines were established by implanting microinjected embryos into C57BL/6J foster mothers. The transgene cassette was found to be intact in these lines by PCR screening using a forward primer in the pLiv11 construct (CTTGGTAAATGTGCTGGGATTAG) and a reverse primer in the hFMO3 cDNA (GATGTCCG-GAACAAACCATTAC). Mendelian inheritance of the transgene was confirmed by 50% positive offspring from each transgenic founder. For all experiments hemizygous positive FMO3-TG mice (pure C57BL/6J background) were crossed to WT C57BL/6J mice to generate hemizygous liver FMO3-TG mice and WT littermate controls.
Microbiota studies and statistical analyses
Microbial community composition was assessed by sequencing the V4 hypervariable region of the 16S rRNA gene derived from mouse cecum [21] . Microbial DNA was isolated using the MoBio PowerSoil DNA isolation kit per the manufacturer's instructions (MoBIO Laboratories, Carlsbad, CA, USA) and sequenced according to previously described methods [34] [35] [36] [37] using the Illumina MiSeq platform. For principal coordinate analyses, each sample's sequences were rarefied to 6000 reads to reduce the effect of sequencing depth. To find operational taxonomic Unit that exhibited significant differences between groups the linear discriminate analysis effect size (LEfSe) analysis was used [38] . A robust Hotelling T2 test was used to examine the difference in the proportion of specific bacterial taxa along with TMAO or occlusion times between treatment groups. False discovery rates (FDRs) of multiple comparisons were estimated for each taxon based on P values resulting from Spearman correlation estimates. All experiments or animal studies were repeated at least three times and values are expressed as mean AE standard error of the mean (SEM) unless otherwise indicated. The Kruskal-Wallis test was used for multiple group comparisons of continuous variables and a chi-squared test was used for categorical variables. The Wilcoxon rank-sum test was used for two-group comparison. Linear mixed-effect models were used for repeated measure analyses. Spearman-rank correlation for non-normally distributed data was used to analyze associations between quantitative variables. For all other statistical tests P < 0.05 was considered significant. Results from all animals in a given experiment were included in analyses using the indicated number of biological replicates. All data were analyzed using R 3.1.0 (Vienna, Austria) and JMP (SAS Institute, Cary, NC, USA).
Results
TMAO enhances murine platelet responsiveness to multiple agonists
Before investigating the role of FMO3 in altering platelet function in vivo we examined the effects of TMAO on mouse platelet function. PRP was isolated from mice maintained on a chemically defined diet (chow: total choline content 0.08 gm%; all mouse plasma TMAO levels < 5 lM). The effect of exogenous TMAO (100 lM vs. vehicle) on platelet aggregation stimulated by multiple distinct agonists (ADP and collagen) was examined. Enhanced platelet aggregation response was observed with submaximal levels of either ADP (Fig. 1A ) or collagen (Fig. 1B) . Further, using isolated washed murine platelets incubated with TMAO (100 lM) vs. controls (normal saline), surface expression level of platelet Pselectin was significantly (P < 0.008) increased in response to submaximal stimulation by ADP (1 lM) in the platelets exposed to TMAO (Fig. 1C,D) .
Antisense oligonucleotide-mediated knockdown of fmo3 reduces TMAO, platelet responsiveness to agonists ex vivo and thrombosis potential in vivo
To determine if the host gene fmo3 impacts platelet function in vivo, we first used ASO-mediated knockdown technology to suppress FMO3 levels in mice maintained on the choline (1 gm%) supplemented diet, as described under Materials and methods. FMO3-ASO treatment (vs. control) significantly reduced both liver FMO3 protein content (P = 0.007; Fig. 2A ) and total liver FMO activity as monitored by flavin-dependent conversion of d9-TMA into d9-TMAO in liver homogenates (P = 0.0003; Fig. 2B ). Although previous studies examining FMO3 ASO treatment of mice on a high-fat, high-cholesterol diet suggest FMO3 may modulate glucose and lipid metabolism [29] , factors known to influence platelet reactivity, in the present studies (not on high-fat/high-cholesterol diet), no effects were observed (Fig. 2C,D) . However, as expected, ASO-mediated knock-down of FMO3 did significantly elevate plasma TMA levels, while concurrently also markedly reducing TMAO levels (P = 0.001 and P < 0.0001, respectively; Fig. 2E,F) . Notably, cecal microbial choline TMA lyase activity measured under anaerobic culture conditions was not significantly impacted by FMO3-ASO treatment (measured as d9- choline ? d9-TMA, P = 0.10; Fig. 2G ). Collectively, these results confirm FMO3 is a major determinant of systemic host conversion of TMA into TMAO in mice and demonstrate that the FMO3-targeted ASO probes used both successfully suppressed hepatic FMO3 protein mass and functionally impaired the conversion TMA into TMAO in vivo.
To evaluate the impact of FMO3-ASO suppression on platelet function and clot formation in vivo, mice were similarly treated (FMO3-targeting vs. control ASO) and then PRP was isolated and platelet responsiveness to ADP-dependent stimulation determined using ex vivo platelet aggregometry. Compared with control ASO, FMO3-ASO treatment again elicited a 3-to 5-fold reduction in plasma TMAO (P < 0.0001) and in parallel, reduction in platelet aggregation response was noted to submaximal (1 lM) ADP stimulation (Fig. 3) . A representative platelet aggregometry tracing from each ASO treatment group is shown in Fig. 3A , and cumulative analyses and TMAO levels for all mice in each of the ASO treatment groups are shown in Fig. 3B . ASO-induced FMO3 suppression resulted in~5-fold reduction in TMAO levels (P < 0.0001), and in parallel, a significant decrease in platelet aggregation response induced by sub-maximal ADP stimulation (P < 0.001; Fig. 3B ). Thus, reduction in FMO3 via an ASO-based approach both suppressed systemic TMAO levels and reduced platelet responsiveness. To further examine the physiological impact of suppression of FMO3 in mice we used an in vivo carotid artery FeCl 3 injury model of thrombosis (Fig. 3C,D) . The overall study design was identical to that used for the ex vivo platelet aggregometry studies, with mice on 1 gm% choline supplemented diet treated with control vs. FMO3-targeted ASO, as indicated. Again, the FMO3-targeted ASO group (relative to control ASO treated) showed significant reduction in TMAO (P < 0.0001), and increases in TMA levels (P < 0.01). Importantly, the control ASO treated (higher TMAO) group showed both faster rate of growing fluorescent intra-luminal platelet clot, and shorter occlusion time, than the FMO3-targeted ASO group following carotid artery injury (P < 0.001; Fig. 3C,D) .
Suppression of fmo3 reduces TMAO levels, and platelet adhesion to matrix in whole blood under physiological sheer stress, but does not impact tail bleeding time
In additional studies we examined the impact of FMO3 on platelet adhesion to collagen in whole blood using a microfluidic device under physiological shear forces (Fig. 4) . For these studies we used a distinct murine FMO3-targeting ASO sequence, as described under Materials and methods. Control studies with both mRNA, western blot analyses (Fig. 4A ) and functional measures of plasma TMA and TMAO levels (Fig. 4A ) and liver total FMO activity (Fig. 4B) all confirmed suppression (all P < 0.001) of host hepatic FMO3 with the FMO3-targeting ASO. Moreover, FMO3 suppression significantly decreased collagen-dependent platelet adhesion to matrix in whole blood under physiological shear force (Fig. 4C) . In additional studies, mice similarly treated with the FMO3-targeted vs. control ASO were examined for tail bleeding time. Despite significant reduction in systemic TMAO levels in the FMO3-ASO group (P < 0.001 vs. control ASO), no differences were observed in bleeding time (P = 0.49; Fig. 4D ).
Liver-specific expression of the human FMO3 transgene enhances systemic TMAO levels, platelet responsiveness to agonists ex vivo and thrombosis potential in vivo
We next sought to test the converse hypotheses, namely, that higher levels of FMO3 in mice can result in higher TMAO levels and enhanced susceptibility to thrombosis. We recently described construction of a liver-specific human FMO3-TG mouse [23] and used this for our initial studies. Because FMO3 expression shows considerable sexual dimorphism in mice and is already highly expressed in the liver of adult female mice (but is much lower in adult male mice) [12, 23] , we were concerned that introduction of the human FMO3 transgene might not further increase TMAO levels compared with WT female mice (i.e. if FMO3 is already in excess in female mice). Indeed, in initial studies we observed that TMAO levels were similar in WT vs. FMO3-TG mice regardless of diet (i.e. plasma TMAO from WT vs. FMO3-TG mice on chow diet, P = 0.97; on choline supplemented diet, P = 0.37, data not shown). In contrast, parallel studies in male mice showed significant increase in circulating TMAO with the introduction of the human FMO3 transgene (n > 5 each genotype, P < 0.01; see below). We therefore performed all FMO3 gain-of-function studies in male mice (WT vs. their heterozygote littermates for the human fmo3 transgene).
Results of initial characterization studies of the male FMO3-TG mice are shown in Fig. 5 . Mice were maintained on the choline supplemented (1 gm%) diets from time of weaning, as described under Materials and methods. As shown, FMO3-TG mice (vs. WT) had higher levels of both hepatic FMO3 mRNA and protein (P < 0.05, each; Fig. 5A ). Functional analyses confirmed the FMO3-TG mice had higher liver FMO activity (measured as flavin-dependent conversion of d9-TMA ? d9-TMAO) than their WT littermates (P = 0.006; Fig. 5B ). No significant change in plasma glucose or cholesterol levels was noted (Fig. 5C, 5D ), but as anticipated, higher TMAO levels were observed (P = 0.0005; Fig. 5F ). Surprisingly, plasma TMA levels in the FMO3-TG mice were also significantly higher than those in WT littermates (P = 0.01; Fig. 5E ), suggesting enhanced microbial production; however, direct measurement of cecal microbial choline TMA lyase activity during anaerobic culture showed no differences between FMO3-TG mice and their WT littermates (P = 0.3; Fig. 5G ).
Because plasma TMAO levels were increased in the male FMO3-TG animals, we proceeded to evaluate the impact of FMO3 transgene on platelet function and thrombosis potential. The higher TMAO levels observed (P < 0.001) in FMO3-TG mice were accompanied by heightened platelet responsiveness to ADP as monitored by platelet aggregometry (Fig. 6A,B ; P < 0.001). To determine whether there is any indication of platelet priming in mice induced solely by FMO3 overexpression, isolated washed platelets from the FMO3-TG vs. WT mice (on chow diet) were examined by flow cytometry for P-selectin surface expression, as described under Materials and methods. No changes in P-selectin levels were noted between the groups (P = 0.67; Fig. 6C ).
In further studies we sought to examine the functional impact of FMO3 overexpression on susceptibility to thrombosis in vivo. Animals were maintained on a choline-supplemented diet and rates of thrombus formation and time to vessel occlusion monitored in the carotid artery following FeCl 3 -induced injury. Notably, the FMO3-TG mice showed higher TMAO levels, which was accompanied by faster clot formation and significantly shorter time to vessel occlusion (P < 0.001; Fig. 6D,E) . In additional analyses we pooled data from all animal studies (both ASO silencing and FMO3 overexpression) and observed a significant relationship between plasma TMAO levels and platelet responsiveness (R = 0.44 (Spearman), P = 0.01; Fig. 7A ).
Genetic manipulation of FMO3 is associated with alteration of gut microbial community
In a final series of studies, because of the observed elevation in TMA in FMO3-TG mice above, and the recent observation that alteration in FMO3 can impact bile acid pool size and composition [29] , which can impact One week prior to study, mice were placed on a 0.5% choline-supplemented diet. On the day of study, (A) liver FMO3 mRNA and plasma TMA and TMAO, liver FMO3 protein by western analysis (n = 4 each group, normalized by Actin) and (B) liver total FMO activity were quantified as described under Materials and methods. Data reported are mean AE SEM (middle line and whiskers) for the indicated numbers of mice. (C) Platelet adhesion in whole blood to a microfluidic chip surface (AE collagen coating) was quantified under physiological sheer as described under Materials and methods. Data represent mean AE SEM adherent platelet area per unit area (l 2 ) of chip surface. Representative images of platelet adhesion from each group at the endpoint following fixation is shown in the images to the right. (D) Tail bleeding time was measured as described in Materials and methods. Data represent mean AE SD (middle line and whiskers) for the indicated numbers of mice. The Wilcoxon rank-sum test was used for two-group comparison. ASO, antisense oligonucleotide; FMO, flavin monooxygenase; SD, standard deviation; SEM, standard error of the mean; TMA, trimethylamine; TMAO, trimethylamine-N-oxide. microbial community structure, we decided to examine whether hepatic human FMO3 overexpression impacted microbial composition in the mice. Cecal microbial DNA was recovered from mice used in in vivo thrombosis model studies, and the DNA encoding 16S ribosomal RNA was analyzed. Significant differences in community structure were observed between microbes recovered from FMO3-TG vs. WT mice as visualized using principal coordinates analysis (Fig. 7B , P < 0.001 for Student's ttest with 1000 Monte Carlo simulations). Subsequent 5 . Characterization of mice with overexpression of human fmo3 transgene. Human FMO3-Transgenic mice and their WT littermates were maintained on a choline-supplemented (1%) diet for 6 weeks as described under Materials and methods. On the day of study, mice were sacrificed and (A) liver FMO3 mRNA (house-keeping gene for normalization was TATA-box binding protein) and protein levels (normalized by Actin) were evaluated. Shown are mean (AE SEM) and western blot images. (B) Liver total FMO activity was quantified in liver homogenates by monitoring the conversion of d9-TMA into d9-TMAO, as described under Materials and methods. Plasma levels of (C) glucose, (D) cholesterol, (E) TMA and (F) TMAO were also quantified as described under Materials and methods. (G) Cecal choline TMA lyase activity was quantified by monitoring the conversion of d9-choline into d9-TMA, as described under Materials and methods. For all plots, data reported are mean (AE SEM) (middle bar and whiskers) for the indicated numbers of mice. The Wilcoxon rank-sum test was used for two-group comparison. FMO, flavin monooxygenase; SEM, standard error of the mean; TMA, trimethylamine; TMAO, trimethylamine-N-oxide; WT, wild-type. examination of the microbial communities using linear discriminant analysis coupled with effect size measurements (LEfSe) [19] identified three cecal microbial taxa whose proportions were characteristic of the FMO3-TG mice (vs. WT littermates), and one taxa characteristic of WT mice (Fig. 7C) . In further analyses (Fig. 7D-G) the proportions of three taxa (Desulfovibrionaceae, Lactobacillus and Dehalobacteriun) recovered from the cecum of FMO3-TG mice were both significantly positively associated with TMAO levels, and negatively associated with occlusion time, the same 3 taxa identified as being characteristic of FMO3-TG mice through LEfSe analyses (Fig. 7C) . Further, the proportions of the genus Odoribacter, which was identified as being characteristic of WT mice (vs. FMO3 heterozygotes; Fig. 7C ), was also observed to be both significantly negatively associated (Fig. 7G) . In further analyses among all mice (both FMO3-TG and WT controls), three taxa were identified whose proportions were significantly associated with quantitative measures of thrombosis potential (occlusion time) in vivo (family Prevotellaceae, genus Prevotella, and genus Desulfovibrionaceae, all FDR adjusted P ≤ 0.01; Fig. 7H ).
Discussion
Normal platelet function is critical to maintain blood hemostasis in a closed circulatory system. And yet, increased platelet responsiveness is associated with elevated CVD risks and heightened rate of thrombotic events. Platelet hyperresponsiveness and thrombosis risk are associated with numerous conditions that predispose to CVD, such as hyperlipidemia [3] , oxidative stress [4] and hyperglycemia [5] . Yet the underlying mechanism(s) remain incompletely understood. We recently showed that the microbe-dependent metabolite, TMAO, directly modulates platelet responsiveness via alteration in calcium release from intracellular pools [19] . Parallel animal model studies showed direct infusion and acute elevation of circulating TMAO can enhance in vivo thrombosis potential in multiple animal models [19] . More recent interventional studies in humans show choline supplementation raises TMAO levels in healthy volunteers (both omnivores and vegans alike) and enhances platelet responsiveness [22] . Moreover, large-scale clinical association studies (e.g. n > 4000 subjects) independently demonstrate that plasma TMAO levels are associated with incident risk of thrombotic events [19] . Interestingly, the heightened thrombosis potential observed with TMAO elevation in vivo may arise not only from alterations in platelet responsiveness, but also alternative mechanisms operative at the artery wall (Fig. 7) . For example, Seldin and colleagues recently reported that direct injection of TMAO in vivo results in vascular inflammation, including arterial endothelial cell activation and upregulation of adhesion proteins through signaling via mitogen-activated protein kinase and NFkB [39] . The metaorganismal pathway responsible for TMAO generation involves both the initiating microbial production of TMA, and the host conversion of TMA into TMAO. In the present studies we utilize multiple independent and complementary approaches to investigate the second half of the TMAO metaorganismal pathway, host FMO3. Using both genetic silencing and gain of function approaches, our studies unambiguously show the involvement of FMO3, via its participation in TMAO generation, as a regulator of both platelet responsiveness and in vivo thrombosis potential. It has been suggested that we are holobionts (i.e. assemblages of both host and all of its symbiotic microbes), and to optimally understand physiology one needs to understand the totality of metabolic processes mediated by both host and microbes within [40] . The present studies build on this concept, and further define a nutrient ? microbe ? host metaorganismal pathway that produces TMAO and consequently alters platelet function and thrombosis potential in vivo (Fig. 8) .
Antiplatelet therapies are a cornerstone of cardiovascular risk reduction in modern medicine [41, 42] . Moreover, the intracoronary arterial sites of culprit lesions in subjects with acute myocardial infarction typically have less than 50% stenosis (e.g. reviewed in [43] ), and it is the acute thrombotic event that precipitates a myocardial infarction, stroke or often sudden cardiac death [44] . Despite their many benefits, antiplatelet agents, including low-dose aspirin, are limited by their tendency to foster unwanted bleeding events [45] [46] [47] . Thus, there is a compelling need to optimize CVD event reduction without accompanying untoward bleeding complications. The present studies suggest targeting the TMAO metaorganismal pathway may be a rational approach. Notably, individuals with a genetic defect in FMO3 have not been reported to have accompanying bleeding complications. Moreover, with FMO3 suppression via ASO, reduced TMAO and both reduced platelet responsiveness and thrombosis potential were observed. Of note, there was no evidence of prolongation of the occlusion time during in vivo thrombosis studies with FMO3 ASO treatment. Although the present studies provide confirmatory support for involvement of this metaorganismal pathway in thrombosis potential, FMO3 remains a poor pharmacological target given the resultant TMA elevation and fish odor that accompanies successful suppression of FMO3 activity. Beyond converting TMA to TMAO, FMOs are also known primarily for their role in metabolism of a wide variety of drugs and environmental pollutants [48] [49] [50] . Thus, pharmacological inhibition of FMO3, although it would potentially reduce host TMAO generation and not impact normal platelet function, would also be predicted to interrupt a central host drug metabolism and detoxification route.
In summary, the present studies further reveal involvement of a gut microbiota-dependent pathway that impacts host vascular function via effects on hemostasis and clot formation. They reaffirm a mechanistic link between dietary choline, a nutrient abundant in a Western diet, gut microbes and host hepatic conversion of the gut microbial intermediate TMA into TMAO, an end product that both impacts platelet function and enhances thrombosis susceptibility. Further studies targeting the TMAO metaorganismal pathway for the treatment of atherothrombotic disease are warranted. 
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